Lilly(Eli) & Co (LLY) concluded trading on Wednesday at a closing price of $724.95, with 4.06 million shares of worth about $2.94 billion changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -2.85% during that period and on May 21, 2025 the price saw a loss of about -2.95%. Currently the company’s common shares owned by public are about 948.10M shares, out of which, 849.67M shares are available for trading.
Stock saw a price change of 1.31% in past 5 days and over the past one month there was a price change of -12.40%. Year-to-date (YTD), LLY shares are showing a performance of -6.09% which decreased to -5.85% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $677.09 but also hit the highest price of $972.53 during that period. The average intraday trading volume for Lilly(Eli) & Co shares is 4.20 million. The stock is currently trading -8.34% below its 20-day simple moving average (SMA20), while that difference is down -8.93% for SMA50 and it goes to -13.47% lower than SMA200.
Lilly(Eli) & Co (NYSE: LLY) currently have 948.10M outstanding shares and institutions hold larger chunk of about 78.90% of that.
The stock has a current market capitalization of $687.06B and its 3Y-monthly beta is at 0.42. PE ratio of stock for trailing 12 months is 60.06, while it has posted earnings per share of $12.07 in the same period. Its PEG reads 1.45 and has Quick Ratio of 1.06 while making debt-to-equity ratio of 2.44. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LLY, volatility over the week remained 2.89% while standing at 3.60% over the month.
Stock’s fiscal year EPS is expected to rise by 67.93% while it is estimated to increase by 36.10% in next year. EPS is likely to grow at an annualized rate of 41.44% for next 5-years, compared to annual growth of 18.77% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by HSBC Securities on April 28, 2025 offering a Reduce rating for the stock and assigned a target price range of between $1150 and $700 to it. Coverage by Cantor Fitzgerald stated Lilly(Eli) & Co (LLY) stock as an Overweight in their note to investors on April 22, 2025, suggesting a price target of $975 for the stock. On December 10, 2024, BofA Securities Resumed their recommendations, while on November 15, 2024, Wolfe Research Initiated their ratings for the stock with a price target of $1000. Stock get an Outperform rating from Bernstein on October 17, 2024.
